This paper reports the antifungal properties of zinc oxide nanoparticles (ZnO NPs) on Candida albicans ATCC 1023 through the study of growth inhibitory effects of ZnO NPs on C. albicans and the effect of the nanoparticles on the surface of C. albicans. The growth inhibitory effects of ZnO NPs (5, 10, 20, 40, 80, and 160 µg/mL) on C. albicans at 24 h were determined through the reduction in suspension turbidity and colony count. Fourier transform infrared (FTIR) analysis was carried out to establish the functional groups associated with the interaction of ZnO NPs on the yeast cell wall, while scanning electron microscopy (SEM) with energy dispersive X-ray (SEM-EDX) analysis was utilised to determine the surface accumulation of ZnO NPs on the yeast cells and the consequential morphological alterations on C. albicans. The results exhibited a significant (p < 0.05) growth inhibition for all tested concentrations except for 5 µg/mL of ZnO NPs at 24 h as compared to negative control. FTIR analysis revealed the possible involvement of alcohol, amide A, methyl, alkynes, amide I and II, and phosphate groups from the cell wall of C. albicans in the surface interaction with ZnO NPs. Finally, SEM-EDX revealed a considerable accumulation of ZnO NPs on the yeast cells and consequential morphological alterations on C. albicans, including the damage of hyphae, pitting of the cell wall, invagination, and rupture of the cell membrane. The current study demonstrated that ZnO NPs possess antifungal properties against C. albicans in a dose-dependent manner, and the surface interaction of ZnO NPs on fungal cells caused alterations in cell membrane integrity that might have resulted in cell death.

Progress in the drug delivery system in the last few decades has led to many advancements for efficient drug delivery. Both micro and nanorobots, are regarded as superior drug delivery systems to deliver drugs efficiently by altering other forms of energy into propulsion and movements. Furthermore, it can be advantageous as it is directed to targeted sites beneath physiological environments and conditions. They have been validated to possess the capability to encapsulate, transport, and supply therapeutic contents directly to the disease sites, thus enhancing the therapeutic efficiency and decreasing systemic side effects of the toxic drugs. This review discusses about the micro-and nanorobots for the diagnostics and management of diseases, types of micro, and nanorobots, role of robots in drug delivery, and its biomedical applications.

Microneedle (MN) delivery devices are more accepted by people than regular traditional needle injections (e.g. vaccination) due to their simplicity and adaptability. Thus, patients of chronic diseases like diabetes look for alternative pain-free treatment regimens circumventing regular subcutaneous injections. Insulin microneedles (INS-MNs) are a thoughtfully researched topic (1) to overcome needle phobia in patients, (2) for controlled delivery of the peptide, (3) decreasing the frequency of drug administration, (4) to ease the drug administration procedure, and (5) thus increasing patient adherence to the treatment dosage regimes. MNs physically disrupt the hard outer skin layer to create minuscule pores for insulin (INS) to pass through the dermal capillaries into the systemic circulation. Biodegradable polymeric MNs are of greater significance for INS and vaccine delivery than silicon, metal, glass, or non-biodegradable polymeric MNs due to their ease of fabrication, mass production, cost-effectiveness, and bioerodability. In recent years, INS-MNs have been researched to deliver INS through the transdermal implants, buccal mucosa, stomach wall, intestinal mucosal layers, and colonic mucosa apart from the usual transdermal delivery. This review focuses on the design characteristics and the applications of biodegradable/dissolvable polymeric INS-MNs in transdermal, intra-oral, gastrointestinal (GI), and implantable delivery. The prospective approaches to formulate safe, controlled-release INS-MNs were highlighted. Biodegradable/dissolvable polymers, their significance, their impact on MN morphology, and INS release characteristics were outlined. The developments in biodegradable polymeric INS-MN technology were briefly discussed. Bio-erodible polymer selection, MN fabrication and evaluation factors, and other design aspects were elaborated.

Transferosomes are one of the vesicular carriers that have received extensive research and attention recently because of their capacity to get beyond the barriers posed by the stratum corneum to penetration. The intent of the current study is to optimize and evaluate proanthocyanidin (PAC) containing transferosomal transdermal gels. PAC-containing transferosomes were prepared using the film hydration method and then loaded into a 4% methylcellulose gel. A 2³ Box–Behnken design was used to optimize the PAC-loaded transferosomal gel, where the effects of phospholipid 90 G (X1), Tween 80 (X2), and sonication time (X3) were evaluated. The formulation factors, such as the drug entrapment efficiency percentage (PEE) and in vitro drug release, were characterized. A PEE of 78.29 ± 1.43% and a drug release in vitro at 6 h of 24.2 ± 1.25% were obtained. The optimized transferosomal-loaded proanthocyanidin (OTP) formulation penetrated the porcine skin at an excellent rate (0.123 ± 0.0067 mg/cm²/h). Stability tests were conducted for OTP to predict the effects of various temperature conditions on the physical appearance, drug content, and PEE for periods of 15, 30, and 45 days. Finally, this transferosomal system for transdermal PAC delivery may be a suitable alternative to the conventional treatment for osteoarthritis.

The major goal of this investigation was to prepare carvedilol nanocrystals (CRL-NCs) for better solubility, stability, and bioavailability. Using polyvinyl pyrolidine K-30 (PVP) and sodium dodecyl sulphate (SDS) as stabilisers, CRL-NCs were effectively synthesised by emulsion-diffusion, followed by the high-pressure homogenization (HPH) method. The A_L classes of phase solubility curves with ideal complexes produced with stabilisers were estimated by thermodynamic parameters. The docking study was performed with the active site of a β-1 adrenoreceptor protein, and the CRLs docking score was revealed as −23.481 Kcal/mol⁻¹. At 25 and 37 °C, the optimum interaction constant was determined for PVP (144 and 176 M⁻¹) and SDS (102 and 121 M⁻¹). The average particle size (PS) of the produced stable CRL-NCs is 58 nm, with a zeta potential of −27.2 ± 2.29 mV, a poly dispersibility index of 0.181 ± 0.012, a percentage yield of 78.7 ± 3.41, drug content of 96.81 ± 3.64%, and entrapment efficiency of 83.61 ± 1.80%. The morphological data also reveals that the CRL-NCs were nearly sphere shaped, with distinct and smooth surfaces. CRL-NCs were studied using X-ray diffraction (XRD), fourier transform infrared (FT-IR) spectroscopy, and differential scanning calorimetry (DSC), and the results show no chemical structural alterations, even when PS was reduced. NCs accelerate their in vitro dissolution release rate by about three times faster than CRL-MCs (microcrystals). When kept at 4 °C, the CRL-NCs exhibit good physical stability for six months. As a result, the CRL-NCs created via emulsion-diffusion followed by HPH with stabilisers can be used to increase the solubility, stability, and bioavailability of poorly soluble or lipophilic drugs.

Zinc oxide nanoparticles (ZnO NPs) are widely used in biomedical applications due to their antimicrobial and antioxidant properties. The objective of the present study was to determine the antifungal activity of ZnO NPs against the yeast Saccharomyces cerevisiae. The turbidity test results showed a significant (p < 0.05) dose-dependent growth inhibitory effect of ZnO NPs on S. cerevisiae as the growth inhibition increased from 7.04 ± 0.64 to 70.30 ± 3.19% as the concentration of ZnO NPs increased from 5 to 150 μg/mL. The scanning microscopy images evidenced the morphological alterations such as regional invagination, pitting, cracks, wrinkles, and cell wall rupture in the yeast cells treated with ZnO NPs. In addition, the FTIR spectrum revealed the possible involvement of hydroxyl, alkene, amides, carbonyl, and phosphate groups from polysaccharides, polypeptides, phospholipids, and ergosterol of the yeast cells wall for binding of ZnO NPs on the cell surface. The present study has demonstrated the antifungal activity of ZnO NPs on S. cerevisiae through growth inhibition and the morphological damages resulting from the treatment of ZnO NPs.